Physician profile
Elisa K Yoo
NPI 1811942493
$8,351.83
in general payments reported to CMS, 2019-2025
43 companies · $2,466 in 2025
The $2,466 reported for 2025 was more than what 91% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $637 · 2021: $767 · 2022: $1,241 · 2023: $890 · 2024: $1,211 · 2025: $2,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,369 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.95 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $986.73 | 2019-2025 | Otezla, Otezla |
| Stryker Corporation | $830.98 | 2019-2022 | |
| Janssen Biotech, INC. | $733.75 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $558.67 | 2019-2025 | |
| Abbvie INC. | $522.76 | 2019-2025 | |
| Genzyme Corporation | $500.45 | 2020-2025 | |
| Incyte Corporation | $411.82 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $368.38 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $358.28 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $357.58 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $310.77 | 2019-2025 | |
| Leo Pharma INC. | $226.37 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $212.31 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Arcutis Biotherapeutics, INC. | $207.56 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $204.58 | 2019-2025 | Odomzo, Blu-U |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $161.92 | 2024-2025 | Klisyri, Seysara |
| Medtronic, INC. | $155.96 | 2022 | |
| Ucb, INC. | $148.13 | 2019-2025 | Bimzelx |
| Optinose US, INC. | $142.63 | 2021-2025 | |
| Genentech USA, INC. | $100.04 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.44 | 2019-2020 | |
| Journey Medical Corporation | $80.48 | 2022-2025 | |
| Intersect Ent, INC. | $69.22 | 2020 | |
| Dusa Pharmaceuticals, INC. | $68.06 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $65.24 | 2024-2025 | Airsupra |
| Dermavant Sciences, INC. | $62.07 | 2024 | Vtama |
| Glaxosmithkline, LLC. | $47.61 | 2022-2023 | Nucala |
| Celgene Corporation | $45.70 | 2019 | |
| Organogenesis INC. | $40.94 | 2025 | Apligraf |
| Phathom Pharmaceuticals, INC. | $26.72 | 2025 | Voquezna |
| Prugen, INC. Pharmaceuticals | $25.05 | 2019 | |
| Neurent Medical Limited | $22.97 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Botanix Sb INC | $22.08 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $22.05 | 2019 | |
| Integra Lifesciences Corporation | $21.75 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Dermira, INC. | $21.48 | 2019 | |
| Misonix INC | $21.11 | 2021 | |
| Inspire Medical Systems, INC. | $19.98 | 2023 | Inspire |
| Helsinn Therapeutics (U.S.), INC. | $19.57 | 2019 | |
| Biofrontera INC. | $18.29 | 2025 | |
| Cipher Pharmaceuticals US LLC | $15.93 | 2025 | Spinosad, Natroba |
| Epi Health, LLC | $15.85 | 2022 | |
| Aclaris Therapeutics, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.